Recent research on clinical trial success rates that caught our eye:   We are especially encouraged to see a group from MIT carrying forward the torch of drug likelihood-of-approval (LOA) analysis. That group of researchers put together this great analysis of what they call Probability of Success ...

Yesterday we completed part 2 of our Safety Biomarkers and Pharmacovigilance webinar. 

This week we introduced the correlation between a company's biomarker coverage in their clinical trial pipeline and their Likelihood of Approval. After showing correlation between approval and biomarker use, we wanted to know more about a company’s biomarker use year over year. As we dove deeper ...

We held a webinar on Tuesday that allowed us to introduce our Biomarker Intelligence Maturity Model and to announce our new partnership with AdisInsight, a member of the Springer Nature family. We can assure you that the two are related.  To see for yourself check out the webinar recording.

Three weeks ago we introduced the concept of the Biomarker Intelligence Maturity Model where we unveiled the 5 stage, 4 swim-lane model representing how companies improve biomarker intelligence management to win in drug and diagnostic development. This is the second installment of that series where ...